On the Divisibility of Trinomials by Maximum Weight Polynomials over F2

Divisibility of trinomials by given polynomials over finite fields has been studied and used to construct orthogonal arrays in recent literature. Dewar et al.\ (Des.\ Codes Cryptogr.\ 45:1-17, 2007) studied the division of trinomials by a given pentanomial over \F_2 to obtain the orthogonal arrays of strength at least 3, and finalized their paper with some open questions. One of these questions is concerned with generalizations to the polynomials with more than five terms. In this paper, we consider the divisibility of trinomials by a given maximum weight polynomial over \F_2 and apply the result to the construction of the orthogonal arrays of strength at least 3.Comment: 10 pages, 1 figur

Some properties of generalized self-reciprocal polynomials over finite fields

Numerous results on self-reciprocal polynomials over finite fields have been studied. In this paper we generalize some of these to a-self reciprocal polynomials defined in [4]. We consider some properties of the divisibility of a-reciprocal polynomials and characterize the parity of the number of irreducible factors for a-self reciprocal polynomials over finite fields of odd characteristic

Highty efficient gene transfer with degradabte poty(ester arnine) based on poty(ethytene gtycol) diacrytate and potyethytenimine in vitro and in vivo

Background Polyethylenimine (PEI) is toxic although it is one of the most successful and widely used gene delivery polymers with the aid of the proton sponge effect. Therefore, development of new novel gene delivery carriers having high efficiency with less toxicity is necessary. Methods In this study, a degradable poly(ester amine) carrier based on poly(ethylene glycol) diacrylate (PEGDA) and low molecular weight linear PEI was prepared. Furthermore, we compared the gene expression of the polymer/DNA complexes using two delivery methods: intravenous administration as an invasive method and aerosol as a non-invasive method. Results The synthesized polymer had a relatively small molecular weight (MW = 7980) with 25 h half-life in vitro. The polymer/DNA complexes were formed at an N/P ratio of 9. The particle sizes and zeta-potentials of the complexes were dependent on N/P ratio. Compared to PEI 25K, the newly synthesized polymer exhibited high transfection efficiency with low toxicity. Poly(ester amine)-mediated gene expression in the lung and liver was higher than that of the conventional PEI carrier. Interestingly, non-invasive aerosol delivery induced higher gene expression in all organs compared to intravenous method in an in vivo mice study. Such an expressed gene via a single aerosol administration in the lung and liver remained unchanged for 7 days. Conclusions Our study demonstrates that poly(ester amine) may be applied as an useful gene carrier. Copyright (C) 2007 John Wiley & Sons, Ltd

Factors for achieving target serum uric acid levels after initiating urate-lowering therapy in patients with gout: results from the ULTRA registry

Abstract Achieving target serum uric acid (SUA) levels is important in gout management. Guidelines recommend lowering SUA levels to < 6 mg/dL; however, many patients fail to reach this target, even with uric acid-lowering therapy (ULT). This study investigated clinical characteristics of target SUA achievers among Korean patients with gout. This study used data from the ULTRA registry, a nationwide inception cohort established in September 2021 that enrolls patients with gout who initiate ULT. Demographic, clinical, and laboratory data were collected at baseline; the 6-month follow-up. Patients were divided into two groups: target achievers (SUA level < 6 mg/dL at 6 months) and non-achievers. The mean participant (N = 117) age was 56.1 years, and 88.0% were male. At 6 months, 83 patients (70.9%) reached target SUA levels. Target achievers had better drug adherence (≥ 80%) to ULT (97.6% vs. 76.5%; p < 0.01) than non-achievers. Target non-achievers had a higher percentage of a family history of gout (32.4% vs. 10.8%; p < 0.01) and less antihypertensive agent use (38.2% vs. 59.0%; p = 0.03) than target achievers. Multivariate regression analysis revealed that good adherence to ULT, the absence of a family history of gout, and antihypertensive agent use were key factors associated with achieving target SUA levels at 6 months

Kaplan-Meier curves for clinical outcomes in the propensity score-matched cohort.

<p>(A) Target lesion failure. (B) Target lesion failure at 1-year landmark. There were no significant differences of clinical outcomes between 2 groups. BP-BES = biodegradable polymer biolimus-eluting stent; DP-EES = durable polymer everolimus-eluting stent.</p